• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coverage

Latest content

Michael Friis

Head of Equities

Michael Friis portrait

Coverage

HydractAudientesRealfictionShape RoboticsScape TechnologiesGreenMobilityCurasightOrderYOYOPenneoPhotocatOdicoAgillicBawat Water TechnologiesImperoMapsPeopleNNITNordic SolarScandinavian Medical SolutionsWindowMaster InternationalGomSpaceCABA CapitalAscelia PharmaEmbla MedicalBioPortoGubraExpreS2ion Biotech

Latest content

ShowingAll content types

MPC Energy Solutions: Guatemala clears its final hurdle, but COD slips into Q3 with a further cash bridge required

Analyst Comment 15.06.2026 klo 12.41 by Michael Friis
MPC Energy Solutions

Curasight: Encouraging preliminary uTREAT® readout de-risks the first of four H2 catalysts

Analyst Comment 08.06.2026 klo 08.22 by Michael Friis
Curasight

Curasight (Investment Case): Four high-value read-outs on track for H2 2026

Research 02.06.2026 klo 13.00 by Michael Friis, Victor Skriver
Curasight

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account

GreenMobility: Launches share buyback programme of up to DKK 6 million

Analyst Comment 01.06.2026 klo 08.30 by Michael Friis
GreenMobility

ExpreS2ion (Investment Case): Q1 2026 - continued progress across pipeline and partner programmes

Research 29.05.2026 klo 09.00 by Michael Friis, Victor Skriver
ExpreS2ion Biotech

ExpreS2ion: Presentation of Q1 2026 report (Recording)

Analyst Comment 28.05.2026 klo 14.02 by Michael Friis
ExpreS2ion Biotech

BioPorto (Investment Case): Q1 2026, advancement on the three pillars central to the long-term potential

Research 22.05.2026 klo 15.30 by Michael Friis, Victor Skriver
BioPorto

SMS (investment case): Second half sets the direction, cost actions and capital reduction in focus

Research 20.05.2026 klo 15.15 by Michael Friis, Victor Skriver
Scandinavian Medical Solutions

ExpreS2ion: Phase I update on ES2B-C001 builds momentum ahead of end-2026 readout

Analyst Comment 19.05.2026 klo 16.25 by Michael Friis
ExpreS2ion Biotech

WindowMaster (Investment case): Macro bites, but structural tailwinds still seem to be there

Research 19.05.2026 klo 16.00 by Michael Friis, Victor Skriver
WindowMaster International